文献速递淋巴瘤

简短R-BM诱导后利妥昔单抗巩固治疗老年晚期滤泡性淋巴瘤的II期研究

A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
PubMed 文献 · Br J Haematol · 2021-01-21

意大利淋巴瘤基金会开展多中心单臂II期试验,评估4周期R-BM方案后4周利妥昔单抗巩固治疗初治老年晚期滤泡性淋巴瘤。76例65-80岁FIT患者入组,完全缓解率78%,总缓解率94%,3年无进展生存67%、总生存92%,中性粒细胞减少为主要严重毒性(18%周期),分子学转阴率高。

要点

  • R-BM方案在FIT老年初治FL患者中完全缓解率达78%,总缓解率94%。
  • 3年PFS为67%,3年OS为92%,中位随访44个月。
  • 治疗结束时可评估患者bcl-2/IGH转阴率达96%。

核心结论

  • 简短R-BM诱导后利妥昔单抗巩固在FIT老年初治晚期FL患者中高效安全,诱导高完全缓解率和分子学缓解率并延长PFS。

研究设计与样本

  • 多中心、单臂II期试验,纳入76例65-80岁、经综合老年评估为FIT的初治滤泡性淋巴瘤患者。
  • 治疗方案为4个月周期利妥昔单抗、苯达莫司汀和米托蒽醌诱导,后予4周利妥昔单抗巩固,未行利妥昔单抗维持。
  • 主要终点为完全缓解率。

主要发现

  • 完全缓解59/76例(78%),部分缓解12例(16%),稳定/进展5例(6%),总缓解率71/76(94%)。
  • 中位随访44个月,3年无进展生存率67%,3年总生存率92%。
  • 9例死亡,其中3例死于疾病进展。
  • 最常见严重毒性为中性粒细胞减少,发生于18%的周期。
  • 可评估患者中bcl-2/IGH重排阳性40/75(53%),治疗结束时29/31(96%)转为bcl-2/IGH阴性。

关键数值与推荐

  • 完全缓解率78%(59/76),总缓解率94%(71/76)。
  • 3年无进展生存率67%,3年总生存率92%。
  • 中性粒细胞减少发生于18%的周期。

临床怎么用

  • 对于FIT老年初治晚期FL患者,可考虑简短R-BM诱导联合利妥昔单抗巩固方案。
  • 治疗中需监测中性粒细胞减少等血液学毒性。
  • 分子学缓解(bcl-2/IGH转阴)可作为疗效参考指标。

局限性

  • 单臂II期研究,无对照组。
  • 入组时利妥昔单抗未获批维持治疗,未应用维持治疗。
  • 样本量有限(76例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment for follicular lymphoma (FL) in the elderly is not well standardized. A phase II, multicentre, single arm trial was conducted in this setting with a brief chemoimmunotherapy regimen. Treatment consisted in four monthly courses of rituximab, bendamustine and mitoxantrone (R-BM) followed by 4 weekly rituximab as consolidation; rituximab maintenance was not applied because the drug was not licensed at the time of enrolment. The primary endpoint was the complete remission rate (CR). Seventy-six treatment-naive FL patients (aged 65-80 and a "FIT" score, according to the Comprehensive Geriatric Assessment) were enrolled. CR was documented in 59/76 patients (78%), partial remission in 12 (16%) and stable/progressive disease in five (6%) with an overall response rate in 71/76 (94%). Median follow-up was 44 months with 3-year progression-free-survival (PFS) and overall-survival of 67% and 92% respectively. Nine deaths occurred, three of progressive disease. The regimen was well tolerated and the most frequent severe toxicity was neutropenia (18% of the cycles). Bcl-2/IGH rearrangement was found in 40/75 (53%) of evaluated patients. R-BM was highly effective in clearing polymerase chain reaction-detectable disease: 29/31 (96%) evaluated patients converted to bcl-2/IGH negativity at the end of treatment. A brief R-BM regimen plus rituximab consolidation is effective and safe in "FIT" elderly, treatment-naïve, FL patients, inducing high CR and molecular remission rates with prolonged PFS.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Boccomini C, Ladetto M, Rigacci L, et al. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). Br J Haematol. 2021. PMID: 33476434. doi:10.1111/bjh.17283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。